JP2003504360A5 - - Google Patents

Download PDF

Info

Publication number
JP2003504360A5
JP2003504360A5 JP2001509712A JP2001509712A JP2003504360A5 JP 2003504360 A5 JP2003504360 A5 JP 2003504360A5 JP 2001509712 A JP2001509712 A JP 2001509712A JP 2001509712 A JP2001509712 A JP 2001509712A JP 2003504360 A5 JP2003504360 A5 JP 2003504360A5
Authority
JP
Japan
Prior art keywords
alkyl
group
ylmethoxy
propoxy
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001509712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003504360A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2000/002566 external-priority patent/WO2001004102A1/en
Publication of JP2003504360A publication Critical patent/JP2003504360A/ja
Publication of JP2003504360A5 publication Critical patent/JP2003504360A5/ja
Withdrawn legal-status Critical Current

Links

JP2001509712A 1999-07-07 2000-07-04 キナゾリン誘導体 Withdrawn JP2003504360A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99401692 1999-07-07
EP99401692.1 1999-07-07
EP00401221 2000-05-04
EP00401221.7 2000-05-04
PCT/GB2000/002566 WO2001004102A1 (en) 1999-07-07 2000-07-04 Quinazoline derivatives

Publications (2)

Publication Number Publication Date
JP2003504360A JP2003504360A (ja) 2003-02-04
JP2003504360A5 true JP2003504360A5 (cg-RX-API-DMAC7.html) 2007-08-02

Family

ID=26073473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001509712A Withdrawn JP2003504360A (ja) 1999-07-07 2000-07-04 キナゾリン誘導体

Country Status (15)

Country Link
US (1) US6806274B1 (cg-RX-API-DMAC7.html)
EP (1) EP1218353B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003504360A (cg-RX-API-DMAC7.html)
KR (1) KR20020029419A (cg-RX-API-DMAC7.html)
CN (1) CN1360582A (cg-RX-API-DMAC7.html)
AT (1) ATE375984T1 (cg-RX-API-DMAC7.html)
AU (1) AU6578900A (cg-RX-API-DMAC7.html)
BR (1) BR0012157A (cg-RX-API-DMAC7.html)
CA (1) CA2378291A1 (cg-RX-API-DMAC7.html)
DE (1) DE60036812T2 (cg-RX-API-DMAC7.html)
ES (1) ES2292461T3 (cg-RX-API-DMAC7.html)
IL (1) IL147280A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01012887A (cg-RX-API-DMAC7.html)
NO (1) NO20020042L (cg-RX-API-DMAC7.html)
WO (1) WO2001004102A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
AU7425801A (en) * 2000-06-24 2002-01-08 Astrazeneca Ab Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
GB0128108D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
EP2292615A1 (en) 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0208224D0 (en) * 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
GB0221245D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Chemical process
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
WO2009059030A1 (en) * 2007-10-31 2009-05-07 Burnham Institute For Medical Research Pyrazole derivatives as kinase inhibitors
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
MX2010012442A (es) 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CN102068434B (zh) * 2011-01-25 2012-08-22 林治华 4-(环己基)-胺基喹唑啉类化合物的应用
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
WO2017040304A1 (en) 2015-08-28 2017-03-09 Cornell University Malt1 inhibitors and uses thereof
WO2018036414A1 (zh) * 2016-08-23 2018-03-01 北京诺诚健华医药科技有限公司 稠杂环类衍生物、其制备方法及其在医学上的应用
US10689366B2 (en) * 2016-11-01 2020-06-23 Cornell University Compounds for MALT1 degredation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659736A (en) * 1984-01-21 1987-04-21 Bayer Aktiengesellschaft Benzoyl urea compounds as agents for repelling snails and slugs
JPH0720943B2 (ja) * 1988-08-19 1995-03-08 宇部興産株式会社 アミノピリミジン誘導体、その製法及び殺虫・殺菌剤
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Il−8受容体拮抗剤
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP1014953B1 (en) * 1997-03-05 2012-04-25 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
WO1998050047A1 (en) 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1019040B1 (en) 1997-05-23 2004-09-29 Bayer Corporation Aryl ureas for the treatment of inflammatory or immunomodulatory diseases
AR016817A1 (es) * 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
ES2292488T3 (es) * 1999-11-16 2008-03-16 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de la urea, como agentes antiinflamatorios.
AU7425801A (en) 2000-06-24 2002-01-08 Astrazeneca Ab Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Similar Documents

Publication Publication Date Title
US7160891B2 (en) Quinazoline derivatives for the treatment of T cell mediated diseases
JP2003535859A5 (cg-RX-API-DMAC7.html)
CA2419301A1 (en) Quinazoline derivatives
US8293902B2 (en) Quinazoline compounds
RU2262935C2 (ru) Производные хиназолина в качестве ингибиторов ангиогенеза
RU2003107683A (ru) Производные хиназолина
JP2007505878A5 (cg-RX-API-DMAC7.html)
EP1218353B1 (en) Quinazoline derivatives
US20090233924A1 (en) Quinazoline derivatives
CA2538884A1 (en) Quinazoline derivatives as tyrosine kinase inhibitors
RU2004116908A (ru) Производные хиназолина в качестве противоопухолевых средств
RU2003118448A (ru) Производные замещенного триазолдиамина и их применение в качестве ингибиторов киназы
JP2007505872A5 (cg-RX-API-DMAC7.html)
JP2008521900A5 (cg-RX-API-DMAC7.html)
CA2483590A1 (en) Use of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy
JP2006506463A5 (cg-RX-API-DMAC7.html)
JP2004508366A5 (cg-RX-API-DMAC7.html)
CA2503371A1 (en) Quinazoline derivatives as src tyrosine kinase inhibitors
JP2024542248A5 (cg-RX-API-DMAC7.html)
JP2006508944A5 (cg-RX-API-DMAC7.html)
US20090036474A1 (en) Quinazoline derivatives for use against cancer
US7001904B1 (en) Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases
US7157467B2 (en) Therapeutic use
RU2002135617A (ru) Хиназолиновые производные для лечения опухолей
US7223756B2 (en) Quinazoline compounds with therapeutic use